Evidence map›Paper›PMID 38197553›Full record

ArticleJournal of veterinary pharmacology and therapeutics2024

Effect of clodronate on gene expression in the peripheral blood of horses.

Callie V Wilcox, Heather K Knych, Scott A Katzman, Rick M Arthur, Veronika Rodriguez, Carrie J Finno

Open access · hybridAbstract readClinical Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Callie V WilcoxDepartment of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA.ORCID https://orcid.org/0000-0001-6963-8043
Heather K KnychK. L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, California, USA.ORCID https://orcid.org/0000-0002-8676-4970
Scott A KatzmanDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, California, USA.
Rick M ArthurSchool of Veterinary Medicine, University of California, Davis, California, USA.
Veronika RodriguezDepartment of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA.
Carrie J FinnoDepartment of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA.ORCID https://orcid.org/0000-0001-5924-0234
University of California, Davis · US

Funding

Students Training in Advanced Research (STAR) ProgramT35OD010956 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DANIKA L BANNASCH · 2012 to 2026
$1.6M
NCATS NIH HHS L40 TR001136NIH HHS T35 OD010956
6 · The paper itself

Abstract

There are two FDA-approved bisphosphonate products, clodronate (Osphos®) and tiludronate (Tildren®), for use in horses. It is hypothesized that bisphosphonates can produce analgesic effects and prevent proper healing of microcracks in bone. Therefore, bisphosphonate use is banned in racehorses. However, bisphosphonates have a short detection window in the blood before sequestration in the skeleton, making the reliability of current drug tests questionable. Seven exercising Thoroughbred horses were administered clodronate (1.8 mg/kg i.m.), and four were administered saline. RNA was isolated from peripheral blood mononuclear cells (PBMCs) collected immediately before a single dose of clodronate or saline and then on Days 1, 6, 28, 56 and 182 post-dose. mRNA was sequenced and analysed for differentially expressed transcripts. While no single transcripts were differentially expressed, pathway analysis revealed that p38 MAPK (p = .04) and Ras (p = .04) pathways were upregulated, and cadherin signalling (p = .02) was downregulated on Day 1. Previously investigated biomarkers, cathepsin K (CTSK) and type 5 acid phosphatase (ACP5), were analysed with RT-qPCR in a targeted gene approach, with no significant difference observed. A significant effect of time on gene expression for ACP5 (p = .03) and CTSK (p < .0001) was observed. Thus, these genes warrant further investigation for detecting clodronate use over time.

Indexed as

Bone Density Conservation AgentsClodronic AcidGene Expression RegulationAnimalsFemaleHorsesLeukocytes, MononuclearMaleBone Density Conservation AgentsClodronic Acidbisphosphonatebloodboneclodronategenehorse

Identifiers

PMID38197553
PMCPMC11052667
OpenAlexW4390695265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.